newsfilter
← Latest News
GlobeNewswire·

Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

PHVS
  • Pharvaris presented Phase 3 CHAPTER-3 results at the ACAAI 2026 Annual Scientific Meeting in Phoenix, Arizona, on November 12, 2026.
  • Deucrictibant XR met all primary & secondary efficacy endpoints, reducing monthly HAE attack rates by 83% across all types & 87% in Type 1 or 2 vs. placebo.
  • 45% of participants on deucrictibant XR remained attack-free during the entire 24-week treatment period, with reductions observed within the first week.
  • The drug demonstrated significant improvements in AE-QoL scores & showed a generally well-tolerated safety profile with no treatment-related serious adverse events.
  • Long-term data from the Phase 2 CHAPTER-1 open-label extension showed sustained attack rate reductions of 92.4% over approximately 34 months.
  • Phase 3 RAPIDe-3 analyses for on-demand treatment showed a median time to end of progression of 17.47 minutes for deucrictibant IR vs. over 3.5 hours for placebo.
  • Pharmacokinetic modeling supports the potential combined use of deucrictibant XR for prophylaxis & deucrictibant IR for on-demand treatment without exceeding safety margins.
  • Integrated cardiovascular safety analyses across 25 studies involving over 740 participants found no evidence of QTc prolongation or increased CV event risks.
  • Real-world economic data revealed that HAE-related medical costs per patient per year increased from $43,271 at baseline to $240,064 during follow-up.
  • Pharvaris continues to develop deucrictibant as an oral bradykinin B2 receptor antagonist for both preventing & treating bradykinin-mediated angioedema attacks.
Company
Pharvaris N.V.
Keywords
Nasdaq:PHVS, Pharvaris N.V.